(Bloomberg) -- Just when a majority of analysts say
Bristol-Myers Squibb Co. has done about all it can for
shareholders, new medicines for diabetes and cancer, together
with takeover speculation, may keep the stock rising.
Seventeen of 23 analysts surveyed by Bloomberg rate the
stock ``hold'' or ``sell'' after the New York-based drugmaker
reached the highest in five years. Bristol-Myers's revived
research pipeline helped the shares to the second-biggest gain
among the eight largest U.S. drugmakers this year.
Read more at Bloomberg Stocks News
Bristol-Myers Squibb Co. has done about all it can for
shareholders, new medicines for diabetes and cancer, together
with takeover speculation, may keep the stock rising.
Seventeen of 23 analysts surveyed by Bloomberg rate the
stock ``hold'' or ``sell'' after the New York-based drugmaker
reached the highest in five years. Bristol-Myers's revived
research pipeline helped the shares to the second-biggest gain
among the eight largest U.S. drugmakers this year.
Read more at Bloomberg Stocks News
